Redox Pathogenesis in Rheumatic Diseases
Top Cited Papers
Open Access
- 25 April 2024
- journal article
- review article
- Published by Wiley in ACR Open Rheumatology
- Vol. 6 (6) , 334-346
Abstract
Despite being some of the most anecdotally well‐known roads to pathogenesis, the mechanisms governing autoimmune rheumatic diseases are not yet fully understood. The overactivation of the cellular immune system and the characteristic development of autoantibodies have been linked to oxidative stress. Typical clinical manifestations, such as joint swelling and deformities and inflammation of the skin and internal organs, have also been connected directly or indirectly to redox mechanisms. The differences in generation and restraint of oxidative stress provide compelling evidence for the broad variety in pathology among rheumatic diseases and explain some of the common triggers and discordant manifestations in these diseases. Growing evidence of redox mechanisms in pathogenesis has provided a broad array of new potential therapeutic targets. Here, we explore the mechanisms by which oxidative stress is generated, explore its roles in autoimmunity and end‐organ damage, and discuss how individual rheumatic diseases exhibit unique features that offer targets for therapeutic interventions.Keywords
Funding Information
- Division of Microbiology and Infectious Diseases (AI072648, AI122176)
- National Institute of Diabetes and Digestive and Kidney Diseases (1F30DK131849)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR076092)
This publication has 174 references indexed in Scilit:
- Evaluation and Treatment of Knee PainJAMA, 2023
- Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population‐Based SurveyArthritis Care & Research, 2015
- Neutrophil Extracellular Trap–Derived Enzymes Oxidize High‐Density Lipoprotein: An Additional Proatherogenic Mechanism in Systemic Lupus ErythematosusArthritis & Rheumatology, 2014
- Brief Report: Anti–Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid ArthritisArthritis & Rheumatism, 2012
- N‐acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2012
- Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblastsArthritis & Rheumatism, 2011
- Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosusArthritis & Rheumatism, 2006
- Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosusArthritis & Rheumatism, 2002
- Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosusArthritis & Rheumatism, 1999
- Deficient γ‐interferon production in patients with systemic lupus erythematosusArthritis & Rheumatism, 1986